Metronomics as maintenance treatment in oncology: Time for chemo-switch

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Malik, Prabhat Singh ^a,b   Raina, Vinod ^b,c   André, Nicolas ^b,d,e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Metronomics Global Health Initiative   (France)

^c Fortis Memorial Research Institute   (India)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e University of the Mediterranean Aix Marseille II   (France)

Author keywords

Chemo switch; Global perspective; Low dose chemotherapy; Maintenance; Metronomic chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; ISOTRETINOIN; METHOTREXATE; PACLITAXEL; PAZOPANIB; TEMOZOLOMIDE;

ABDOMINAL PAIN; ANEMIA; ANGIOGENESIS; ARTHRALGIA; CANCER GROWTH; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DYSPNEA; FATIGUE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NOTE; ONCOLOGY; OVARY CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; VOMITING;

EID: 84901001797     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00076     Document Type: Note

References (58)

1. Gatenby RA. A change of strategy in the war on cancer. Nature (2009) 28(7246):508-9. doi:10.1038/459508a.
2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest (2000) 105(8):1045-7. doi:10.1172/JCI9872.
3. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 105(8):R15-24. doi:10.1172/JCI8829.
4. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 60(7):1878-86.
5. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 7(8):455-65. doi:10.1038/nrclinonc.2010.82.
6. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2007) 56(5):641-8. doi:10.1007/s00262-006-0225-8.
7. André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol (2014) (in press).
8. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer (2013) 49(16):3387-95. doi:10.1016/j.ejca.2013.06.038.
9. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol (2013) 31(8):1009-20. doi:10.1200/JCO.2012.43.7459.
10. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol (1997) 98(4):945-51. doi:10.1046/j.1365-2141.1997.3113127.x.
11. Mauer AM. Therapy of acute lymphoblastic leukemia in childhood. Blood (1980) 56(1):1-10.
12. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol (2009) 27(10):1607-14. doi:10.1200/JCO.2008.17.1561.
13. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet (2011) 377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7.
14. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest (2011) 140(1):117-26. doi:10.1378/chest.10-2745.
15. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 29(16):2144-9. doi:10.1200/JCO.2010.31.5374.
16. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol (2006) 24(3):394-400. doi:10.1200/JCO.2005.03.0106.
17. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 25(12):1539-44. doi:10.1200/JCO.2006.09.6305.
18. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 26(12):2013-9. doi:10.1200/JCO.2007.14.9930.
19. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol (2003) 21(13):2460-5. doi:10.1200/JCO.2003.07.013.
20. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol (2009) 27(28):4642-8. doi:10.1200/JCO.2009.21.9691.
21. Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev (2013) 6:CD007414. doi:10.1002/14651858.CD007414.pub3.
22. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol (2012) 30(17):2039-45. doi:10.1200/JCO.2012.42.0505.
23. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 366(15):1382-92. doi:10.1056/NEJMoa1105535.
24. Du Bois A, Floquet A, Kim JW, Rau J, Campo JMD, Friedlander M, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol (2013) 31(Suppl 18):LBA5503.
25. Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol (2010) 5(8):1263-72. doi:10.1097/JTO.0b013e3181e15d16.
26. Lesnock JL, Farris C, Krivak TC, Smith KJ, Markman M. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol (2011) 122(3):473-8. doi:10.1016/j.ygyno.2011.05.014.
27. Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer (2014) 50(1):40-9. doi:10.1016/j.ejca.2013.08.008.
28. Juhász E, Kim J-H, Klingelschmitt G, Walzer S. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer (2013) 49(6):1205-15. doi:10.1016/j.ejca.2012.11.006.
29. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol (2012) 13(3):292-9. doi:10.1016/S1470-2045(11)70339-4.
30. Peeters L, Sibille A, Anrys B, Oyen C, Dooms C, Nackaerts K, et al. Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions. J Thorac Oncol (2012) 7(8):1291-5. doi:10.1097/JTO.0b013e31825879ea.
31. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2005) 23(5):939-52. doi:10.1200/JCO.2005.07.093.
32. Vives M, Ginestà MM, Gracova K, Graupera M, Casanovas O, Capellà G, et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer (2013) 133(10):2464-72. doi:10.1002/ijc.28259.
33. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 67(8):3560-4. doi:10.1158/0008-5472.CAN-06-4238.
34. Koopman M, Simkens LH, Tije AJT, Creemers G-J, Loosveld OJ, de Jongh FE, et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). oral abstract session, gastrointestinal (colorectal) cancer. J Clin Oncol (2013) (suppl; abstr 3502).
35. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol (2003) 21(15):2933-9. doi:10.1200/JCO.2003.02.563.
36. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol (2008) 26(3):468-73. doi:10.1200/JCO.2007.13.1912.
37. Sun JF, Wu RR, Norris C, Noone A-M, Amankwa-Sakyi M, Slack R, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res (2009) 3(4):134-40.
38. Choi LMR, Rood B, Kamani N, La Fond D, Packer RJ, Santi MR, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer (2008) 50(5):970-5. doi:10.1002/pbc.21381.
39. Gadducci A, Katsaros D, Zola P, Scambia G, Ballardini M, Pasquini E, et al. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second- look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int J Gynecol Cancer (2009) 19(4):615-9. doi:10.1111/IGC.0b013e3181a4476b.
40. Aurilio G, Sciandivasci E, Munzone E, Riva DF, Radice D, Bertolini F, et al. First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): preliminary analysis of a monocentric phase II trial. J Clin Oncol (2011) 29(15 suppl): e11547.
41. Kamat AA, Kim TJ, Landen CN Jr., Lu C, Han LY, Lin YG, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 67(1):281-8. doi:10.1158/0008-5472.CAN-06-3282.
42. Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res (2013) 73(9):2743-8. doi:10.1158/0008-5472.CAN-12-4183.
43. Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC, Neubauer NL. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol (2013) 24(3):258-64. doi:10.3802/jgo.2013.24.3.258.
44. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol (2011) 29(15):1997-2003. doi:10.1200/JCO.2010.29.4496.
45. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 30(25):3084-92. doi:10.1200/JCO.2011.39.7646.
46. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer (2011) 11(2):82-92. doi:10.1016/j.clbc.2011.03.005.
47. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 30(9):921-9. doi:10.1200/JCO.2011.35.7376.
48. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther (2010) 9(4):985-95. doi:10.1158/1535-7163.MCT-09-0967.
49. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs (2007) 67(6):821-45. doi:10.2165/00003495-200767060-00001.
50. Olsen SR. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomed Pharmacother (2005) 59(Suppl 2):S306-10. doi:10.1016/S0753-3322(05)80052-6.
51. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab (2013) 24(9):469-80. doi:10.1016/j.tem.2013.05.004.
52. Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res (2014) 159:355-76. doi:10.1007/978-3-642-38007-5_21.
53. Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer (2013) 108(12):2485-94. doi:10.1038/bjc.2013.205.
54. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget (2011) 2(10):797-809.
55. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev (2008) 34(3):206-22. doi:10.1016/j.ctrv.2007.11.003.
56. Gao Y, Lu X-C, Yang H-Y, Liu X-F, Cao J, Fan L. The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses. Int J Mol Med (2012) 30(4):765-74. doi:10.3892/ijmm.2012.1054.
57. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res (2011) 71(21):6764-72. doi:10.1158/0008-5472.CAN-11-0691.
58. André N, Banavali S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol (2013) 14(6):e239-48. doi:10.1016/S1470-2045(13)70056-1.